MedPath

Alanosine in Treating Patients With Cancer

Phase 2
Completed
Conditions
Lung Cancer
Malignant Mesothelioma
Pancreatic Cancer
Sarcoma
Registration Number
NCT00062283
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Brief Summary

RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well alanosine works in treating patients with soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.

Detailed Description

OBJECTIVES:

* Determine the response rates in patients with methylthioadenosine phosphorylase (MTAP)-deficient cancer when treated with alanosine.

* Determine the time to response and duration of response in patients treated with this drug.

* Determine the progression-free survival of patients treated with this drug.

* Determine the pharmacodynamic activity of this drug in these patients, based on special imaging to measure tumor adenosine triphosphate depletion.

* Determine the pharmacokinetic activity of this drug in these patients.

* Determine the safety and tolerability of this drug in these patients.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

Patients receive alanosine IV continuously on days 1-5. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 28 days.

PROJECTED ACCRUAL: A total of 50-145 patients (10-29 per tumor type) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (12)

Lynn Regional Cancer Center West

🇺🇸

Boca Raton, Florida, United States

MD Anderson Cancer Center at University of Texas

🇺🇸

Houston, Texas, United States

Arizona Cancer Center at University of Arizona Health Sciences Center

🇺🇸

Tucson, Arizona, United States

Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center

🇺🇸

Los Angeles, California, United States

University of Alabama at Birmingham Comprehensive Cancer Center

🇺🇸

Birmingham, Alabama, United States

Wilshire Oncology Medical Group, Incorporated - La Verne

🇺🇸

La Verne, California, United States

University of Chicago Cancer Research Center

🇺🇸

Chicago, Illinois, United States

Midwest Cancer Research Group, Incorporated

🇺🇸

Skokie, Illinois, United States

St. Vincent's Comprehensive Cancer Center - Manhattan

🇺🇸

New York, New York, United States

Memorial Sloan-Kettering Cancer Center

🇺🇸

New York, New York, United States

Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center

🇺🇸

Nashville, Tennessee, United States

U.S. Oncology, Incorporated

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath